Floatz logo

Hyperacute®-Renal Immunotherapy

Metastatic Kidney Cancer

NewLink Genetics CorporationPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

70 Active assets in the Metastatic Kidney Cancer cohort.

Asset / SponsorPhaseRating
Alpha-Interferon
Dartmouth-Hitchcock Medical Center
Phase 3BBB
Girentuximab
Memorial Sloan Kettering Cancer Center
Phase 3BB
Girentuximab
Heidelberg Pharma AG
Phase 3BB
ETOPOSIDE
City of Hope Medical Center
Phase 3BB
FLUOROURACILUM
Medical Research Council
Phase 3BB

View all 50 →

Same molecule, other indications

Hyperacute®-Renal Immunotherapy is also rated in:

renal cell carcinomaDormant
CC
Indicative ·
44 / 100
View asset →
nonpapillary renal cell carcinomaDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →